Terms: = Breast cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
72 results:
1. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
2. Deciphering the Immune Microenvironment at the Forefront of Tumor Aggressiveness by Constructing a Regulatory Network with Single-Cell and Spatial Transcriptomic Data.
Xu K; Yu D; Zhang S; Chen L; Liu Z; Xie L
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254989
[TBL] [Abstract] [Full Text] [Related]
3. ezh2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
4. Validation of ezh2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
5. ezh2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the ezh2-E-cadherin/RHOB pathway.
Lei C; Li S; Fan Y; Hua L; Pan Q; Li Y; Long Z; Yang R
Cancer Biol Ther; 2022 Dec; 23(1):1-13. PubMed ID: 36329030
[TBL] [Abstract] [Full Text] [Related]
7. Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.
Peng W; Tang W; Li JD; He RQ; Luo JY; Chen ZX; Zeng JH; Hu XH; Zhong JC; Li Y; Ma FC; Xie TY; Huang SN; Ge LY
PeerJ; 2022; 10():e13708. PubMed ID: 35846880
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of precision targeting ezh2 degraders for triple-negative breast cancer.
Wang C; Chen X; Liu X; Lu D; Li S; Qu L; Yin F; Luo H; Zhang Y; Luo Z; Cui N; Kong L; Wang X
Eur J Med Chem; 2022 Aug; 238():114462. PubMed ID: 35623249
[TBL] [Abstract] [Full Text] [Related]
9. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
10. METTL3 Accelerates breast cancer Progression via Regulating ezh2 m
Hu S; Song Y; Zhou Y; Jiao Y; Li G
J Healthc Eng; 2022; 2022():5794422. PubMed ID: 35392146
[TBL] [Abstract] [Full Text] [Related]
11. ezh2 Protein Expression in Triple-negative breast cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and prognosis.
Fineberg S; Tian X; Makower D; Harigopal M; Lo Y
Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):157-164. PubMed ID: 35262520
[TBL] [Abstract] [Full Text] [Related]
12. CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
Nasif D; Real S; Roqué M; Branham MT
Breast Cancer; 2022 May; 29(3):562-573. PubMed ID: 35094293
[TBL] [Abstract] [Full Text] [Related]
13. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
J Genet; 2021; 100():. PubMed ID: 34825659
[No Abstract] [Full Text] [Related]
14. HOXD9 transcriptionally induced UXT facilitate breast cancer progression via epigenetic modification of RND3.
Hu XC; Chu J; Zhou Y; Li CC; Zhou GJ; Jiang GQ
Cell Signal; 2022 Feb; 90():110188. PubMed ID: 34767964
[TBL] [Abstract] [Full Text] [Related]
15. Long Noncoding RNA GAS5 in breast cancer: Epigenetic Mechanisms and Biological Functions.
Filippova EA; Fridman MV; Burdennyy AM; Loginov VI; Pronina IV; Lukina SS; Dmitriev AA; Braga EA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202777
[TBL] [Abstract] [Full Text] [Related]
16. NOTCH and ezh2 collaborate to repress PTEN expression in breast cancer.
Pappas K; Martin TC; Wolfe AL; Nguyen CB; Su T; Jin J; Hibshoosh H; Parsons R
Commun Biol; 2021 Mar; 4(1):312. PubMed ID: 33750924
[TBL] [Abstract] [Full Text] [Related]
17. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer.
Chang PH; Chen MC; Tsai YP; Tan GYT; Hsu PH; Jeng YM; Tsai YF; Yang MH; Hwang-Verslues WW
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431674
[TBL] [Abstract] [Full Text] [Related]
18. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
[TBL] [Abstract] [Full Text] [Related]
19. Both ezh2 and JMJD6 regulate cell cycle genes in breast cancer.
Biswas A; Mukherjee G; Kondaiah P; Desai KV
BMC Cancer; 2020 Nov; 20(1):1159. PubMed ID: 33246425
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Wang L; Wang Y; Su B; Yu P; He J; Meng L; Xiao Q; Sun J; Zhou K; Xue Y; Tan J
Sci Rep; 2020 Oct; 10(1):16504. PubMed ID: 33020551
[TBL] [Abstract] [Full Text] [Related]
[Next]
